NASDAQ: INM
Inmed Pharmaceuticals Inc Stock Ownership - Who owns Inmed Pharmaceuticals?

Insider buying vs selling

Have Inmed Pharmaceuticals Inc insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when INM insiders and whales buy or sell their stock.

INM Shareholders

What type of owners hold Inmed Pharmaceuticals Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Shane Aaron Johnson24.45%583,023$1.08MInsider
Eric A. Adams1.84%43,959$81.32kInsider
Andrew Hull1.60%38,258$70.78kInsider
Bruce Colwill0.48%11,515$21.30kInsider
Ubs Group Ag0.33%7,762$14.36kInstitution
Tower Research Capital LLC Trc0.02%400$740.00Institution
Sbi Securities Co Ltd0.01%300$555.00Institution
Banque Cantonale Vaudoise0.00%6$11.10Institution
Allsquare Wealth Management LLC0.00%1$1.85Institution
Bessemer Group Inc0.00%1$1.85Institution

1 of 2

INM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
INM0.36%28.39%
CNSP31.08%68.92%
CMND10.96%0.00%
GRI0.71%99.29%
JAGX0.13%99.87%

Inmed Pharmaceuticals Stock Ownership FAQ

Who owns Inmed Pharmaceuticals?

Inmed Pharmaceuticals (NASDAQ: INM) is owned by 0.36% institutional shareholders, 28.39% Inmed Pharmaceuticals insiders, and 71.26% retail investors. Shane Aaron Johnson is the largest individual Inmed Pharmaceuticals shareholder, owning 583,023.00 shares representing 24.45% of the company. Shane Aaron Johnson's Inmed Pharmaceuticals shares are currently valued at $1.10M.

If you're new to stock investing, here's how to buy Inmed Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.